QQ客服 官方微博 反馈留言

	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer
	Xing, Puyuan; Mu, Yuxin; Wang, Yan; Hao, Xuezhi; Zhu, Yixiang; Hu, Xingsheng; Wang, Hongyu; Liu, Peng; Lin, Lin; Wang, Zhijie
	2018
卷号	9期号:12页码:1716-1724
关键词	Bevacizumab beyond progression non-small cell lung cancer overall survival safety
ISSN号	1759-7706
DOI	10.1111/1759-7714.12886
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6353072
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Xing, Puyuan,Mu, Yuxin,Wang, Yan,et al. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer[J],2018,9(12):1716-1724.
APA	Xing, Puyuan.,Mu, Yuxin.,Wang, Yan.,Hao, Xuezhi.,Zhu, Yixiang.,...&Li, Junling.(2018).Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.,9(12),1716-1724.
MLA	Xing, Puyuan,et al."Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer".9.12(2018):1716-1724.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。